京新药业（002020.SZ）9月15日在投资者互动平台表示，公司LP（a）机制降脂新药目前处于临床I期， 对外授权工作在进展中，具体进展敬请关注相关公告。 （记者 谭玉涵） 每经AI快讯，有投资者在投资者互动平台提问：公司LPa降脂新药BD业务到什么程度了，几个月前就 说在洽谈该项业务。难道公司效率都这么慢吗？ ...

Group 1 - The company currently has several innovative drugs in clinical trials, including JX11502 capsules, rehabilitation new enteric-coated capsules, and LP(a) mechanism lipid-lowering drugs [2] - The company has expressed interest in overseas business development for some of its innovative drugs [2] - The company assures that its pipeline for innovative drug development is robust and sufficient for future growth [2]